Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D03JCA
|
||||
Former ID |
DIB003870
|
||||
Drug Name |
MB-11055
|
||||
Synonyms |
Cryptotanshinone, MD BioAlpha; Cryptotanshinone, Mazence; AMP activated protein kinase stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; AMPK stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; Lipid metabolism stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence
|
||||
Indication | Fatty liver disease [ICD10:K70, K76.0] | Phase 2 | [549310] | ||
Company |
Mazence Inc
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
C[C@H]1COC2=C1C(=O)C(=O)c3c4CCCC(C)(C)c4ccc23
|
||||
InChI |
1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m0/s1
|
||||
InChIKey |
GVKKJJOMQCNPGB-JTQLQIEISA-N
|
||||
Target and Pathway | |||||
Target(s) | AMP-activated protein kinase | Target Info | Modulator | ||
KEGG Pathway | FoxO signaling pathway | ||||
Regulation of autophagy | |||||
mTOR signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
AMPK signaling pathway | |||||
Circadian rhythm | |||||
Insulin signaling pathway | |||||
Adipocytokine signaling pathway | |||||
Oxytocin signaling pathway | |||||
Glucagon signaling pathway | |||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Hypertrophic cardiomyopathy (HCM) | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.